Clinical trials: Multiple Sclerosis, Primary Progressive
Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
This is a Phase 3 extension, global, multicenter study to assess the long-term safety and tolerability of tolebrutinib in adult participants (aged ≥18 years) with RMS, PPMS, or NRSPMS who were previously enrolled in the Phase 2b…
- Conditions
- Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
- Trial name
- NCT06372145
- Testing
- Tolebrutinib, Teriflunomide
- Where
- 352 sites in United States, Argentina and 45 more
- Volunteers
- 2,500 people
- Sponsor
- Sanofi
Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis
PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPF
This is a study of PIPE-791, an investigational study drug to treat progressive multiple sclerosis (MS) and idiopathic pulmonary fibrosis (IPF).
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis, Multiple Sclerosis, Multiple Sclerosis, MS
- Trial name
- NCT06683612
- Testing
- PIPE-791
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Contineum Therapeutics
Primary Progressive Multiple Sclerosis
This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.
The purpose of this study is to evaluate whether FTY720 is effective in delaying MS disability progression compared to placebo in patients with PPMS.
- Trial name
- INFORMS (NCT00731692)
- Testing
- FTY720
- Where
- 157 sites in United States, Australia and 16 more
- Volunteers
- 970 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive
An Observational Biomarker Study in Multiple Sclerosis (MS) Patients
All males and females between 18-70 years of age regardless of their race and ethnicity with a confirmed diagnosis of Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS), and Relapse…
- Conditions
- Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
- Trial name
- NCT05663853
- Where
- 4 sites in United States
- Volunteers
- 137 people
- Sponsor
- LAPIX Therapeutics Inc.
Multiple Sclerosis
Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
The primary objective of this expanded access program is to provide ocrelizumab as treatment for eligible participants with primary progressive multiple sclerosis (PPMS) before it is commercially available in the United States…
- Trial name
- NCT02807285
- Testing
- Ocrelizumab
- Where
- 56 sites in United States
- Sponsor
- Genentech, Inc.
Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Refractory Primary and Secondary Progressive Multiple Sclerosis
- Conditions
- Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, MS
- Trial name
- NCT06384976
- Testing
- KYV-101, Standard lymphodepletion regimen, Anti-CD20 mAB
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Kyverna Therapeutics
Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS)
Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
The goal of this clinical trial is to treat male and female participants with two types of Multiple Sclerosis (MS) called primary progressive or secondary progressive MS.
- Conditions
- Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS), Multiple Sclerosis, Multiple Sclerosis (MS) Primary Progressive
- Trial name
- IMPACT-MS (NCT07477639)
- Testing
- TRX319, Bendamustine
- Where
- 8 sites in United States
- Volunteers
- 39 people
- Sponsor
- Tr1X, Inc.
Multiple Sclerosis, Primary Progressive Multiple Sclerosis
C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Progressive Multiple Sclerosis Refractory to Standard Therapy
This is a global, multicenter, Phase 1b/2 study evaluating the safety and efficacy of C-CAR168, an autologous anti-CD20/BCMA chimeric antigen receptor T-cell therapy, in participants with progressive multiple sclerosis refractory…
- Conditions
- Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary Progress Multiple Sclerosis (SPMS), Primary Progressive Multiple Sclerosis (PPMS)
- Trial name
- NCT07825389
- Testing
- C-CAR168
- Where
- 2 sites in United States
- Volunteers
- 119 people
- Sponsor
- AbelZeta Inc.
Multiple Sclerosis, Primary Progressive
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis
A study to evaluate the efficacy and safety of fenebrutinib on disability progression in adult participants with Primary Progressive Multiple Sclerosis (PPMS).
- Trial name
- FENtrepid (NCT04544449)
- Testing
- Fenebrutinib, Ocrelizumab
- Where
- 190 sites in United States, Argentina and 26 more
- Volunteers
- 985 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis
A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy
The purpose of this study is to assess the imaging biomarkers, patient outcomes, safety, tolerability, and treatment satisfaction of ocrelizumab (OCR) combined with recombinant human hyaluronidase (rHuPH20) administered…
- Trial name
- OSSIA (NCT07609719)
- Testing
- OCR SC
- Where
- 5 sites in United States, Puerto Rico
- Volunteers
- 100 people
- Sponsor
- Genentech, Inc.
Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis
The purpose of the study is to determine the safety and tolerability, dose-limiting toxicities, maximum tolerated dose, and recommended therapeutic dose of intravenously administered MIS416 weekly in patients with chronic…
- Trial name
- NCT01191996
- Testing
- MIS416
- Where
- New Zealand
- Volunteers
- 34 people
- Sponsor
- Innate Immunotherapeutics
Multiple Sclerosis, Primary Progressive
A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
This randomized, parallel group, double-blind, placebo controlled study will evaluate the efficacy and safety of ocrelizumab in participants with primary progressive multiple sclerosis.
- Trial name
- NCT01194570
- Testing
- Ocrelizumab
- Where
- 184 sites in United States, Australia and 27 more
- Volunteers
- 735 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)
This is a randomized, double blind, controlled, parallel group, multicenter study to evaluate efficacy, safety and PK of a higher dose of ocrelizumab per intravenous (IV) infusion every 24 weeks (Q24W) in participants with PPMS…
- Trial name
- GAVOTTE (NCT04548999)
- Testing
- Ocrelizumab, Antihistamine, Methylprednisolone
- Where
- 147 sites in United States, Argentina and 20 more
- Volunteers
- 769 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis
The main purpose of this study is to evaluate the safety and tolerability of the ocrelizumab subcutaneous (SC) test formulation in participants with multiple sclerosis (MS).
- Trial name
- OCARINA 3 (NCT07667322)
- Testing
- Ocrelizumab Co-formulated With rHuPH20
- Where
- 12 sites in United States, Brazil and 2 more
- Volunteers
- 75 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study designed to evaluate the safety, tolerability and activity of ibudilast administered twice daily over a 96 week period in subjects with…
- Trial name
- NCT01982942
- Testing
- ibudilast
- Where
- 28 sites in United States
- Volunteers
- 255 people
- Sponsor
- MediciNova
Primary Progressive Multiple Sclerosis
Safety and Efficacy of Monthly Long-acting IM Injection of 25mg or 40 mg GA Depot in Subjects With PPMS
This is a phase IIa study with GA Depot in subjects with Primary Progressive MS. GA Depot will be administered intramuscularly (IM), once every four weeks for 148 weeks.
- Trial name
- NCT03362294
- Testing
- GA Depot 40mg once monthly, GA Depot 25mg once monthly
- Where
- 7 sites in Israel, Moldova
- Volunteers
- 30 people
- Sponsor
- Mapi Pharma Ltd.
Multiple Sclerosis
A Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis
This is a Phase II/III, randomized, double-blind, parallel group, placebo controlled, multicenter study to evaluate the safety and efficacy of rituximab in adults with PPMS.
- Trial name
- OLYMPUS (NCT00087529)
- Testing
- rituximab
- Volunteers
- 439 people
- Sponsor
- Genentech, Inc.
Primary Progressive Multiple Sclerosis, Primary Progressive MS
A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)
The goal of this Phase 2 clinical trial is to investigate the safety and tolerability of SUN-627 in men and women aged 18-70 years old with a diagnosis of non-active SPMS/PPMS.
- Conditions
- Primary Progressive Multiple Sclerosis, Primary Progressive MS, Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive MS (SPMS)
- Trial name
- NCT07840326
- Testing
- SUN-627
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Sundance Biosciences, Inc.
Multiple Sclerosis
A Study to Evaluate the Safety of Administering Ocrelizumab Per a Shorter Infusion Protocol in Participants With Primary Progressive Multiple Sclerosis (PPMS) and Relapsing Multiple Sclerosis (RMS)
This study is an open-label, non-randomized study to evaluate rate and severity of infusion-related reactions (IRRs) of ocrelizumab infused over a shorter time period than the approved administration rate in participants with…
- Trial name
- NCT03606460
- Testing
- Ocrelizumab Dose 1, Ocrelizumab Dose 2 and Dose 3
- Where
- 5 sites in United States
- Volunteers
- 141 people
- Sponsor
- Genentech, Inc.
Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis
The main purpose of this study is to evaluate the efficacy of ocrelizumab in participants with relapsing multiple sclerosis (RMS) and to characterize the ocrelizumab pharmacodynamic (PD) profile in Chinese participants with…
- Trial name
- NCT07483450
- Testing
- Ocrelizumab
- Where
- 17 sites in China
- Volunteers
- 60 people
- Sponsor
- Hoffmann-La Roche